• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjectsProfilesView

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer.

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Thumbnail
    Name:
    s00280-018-3532-9.pdf
    Size:
    988.1Kb
    Format:
    PDF
    Description:
    Full text, Open Access article
    Download
    Authors
    Morgan, Robert David
    Clamp, Andrew R
    Evans, D
    Edmondson, R
    Jayson, Gordon C
    Affiliation
    Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK
    Issue Date
    2018-04
    
    Metadata
    Show full item record
    Abstract
    Poly(ADP-ribose) polymerase inhibitors (PARPi) have changed the management of high-grade serous ovarian cancer (HGSOC). The rationale for the development of PARPi was based on the concept of synthetic lethality, in which a cell can survive a deficiency of one gene/gene product, but may die if there is a deficiency in a combination of genes/gene products. In women with BRCA1/2 deficiency within their ovarian cancer tissue, inhibition of PARP imposes an intolerable burden of DNA damage repair deficiency and may induce cell death.
    Citation
    PARP inhibitors in platinum-sensitive high-grade serous ovarian cancer. 2018, 81(4): 647-658 Cancer Chemother Pharmacol
    Journal
    Cancer Chemotherapy and Pharmacology
    URI
    http://hdl.handle.net/10541/620923
    DOI
    10.1007/s00280-018-3532-9
    PubMed ID
    29464354
    Type
    Article
    Language
    en
    ISSN
    1432-0843
    ae974a485f413a2113503eed53cd6c53
    10.1007/s00280-018-3532-9
    Scopus Count
    Collections
    All Christie Publications

    entitlement

    Related articles

    • Sequential Targeting of PLK1 and PARP1 Reverses the Resistance to PARP Inhibitors and Enhances Platin-Based Chemotherapy in BRCA-Deficient High-Grade Serous Ovarian Cancer with KRAS Amplification.
    • Authors: Gasimli K, Raab M, Tahmasbi Rad M, Kurunci-Csacsko E, Becker S, Strebhardt K, Sanhaji M
    • Issue date: 2022 Sep 17
    • Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment.
    • Authors: Papa A, Caruso D, Strudel M, Tomao S, Tomao F
    • Issue date: 2016 Sep 15
    • Real-world Study on the Effect of PARPi as Maintenance Therapy on Platinum Sensitivity after First- and Second-line Chemotherapy in Patients with Recurrent High-grade Serous Epithelial Ovarian Cancer.
    • Authors: Guo Y, Chen X, Tang X, Pan S, Zhu T, Zhang Y
    • Issue date: 2024
    • Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.
    • Authors: Ledermann JA, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T, Matei D, Fielding A, Spencer S, Rowe P, Lowe E, Hodgson D, Sovak MA, Matulonis U
    • Issue date: 2016 Nov
    • Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer.
    • Authors: Ivy SP, Liu JF, Lee JM, Matulonis UA, Kohn EC
    • Issue date: 2016
    DSpace software (copyright © 2002 - 2025)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.